All News
Filter News
Found 174 articles
-
Three of Vivek Ramaswamy’s companies reported activity today including corporate changes, a licensed therapy and investment of $100 million.
-
Roivant Sciences Provides Corporate Update
8/28/2018
Dr. Frank Torti, former partner at NEA, appointed Vant Investment Chair
-
Sinovant Sciences, Company Focused on the Development of Innovative Medicines in China, Unveiled at Event in Beijing
7/17/2018
Backed by Roivant Sciences and CITICPE, a leading Chinese asset management firm
-
Months after tapping GlaxoSmithKline dermatology division executive David Rubenstein as its new chief scientific officer, Vivek Ramaswamy’s Dermavant Sciences has returned to the pharma giant to acquire a Phase III-ready psoriasis treatment.
-
Roivant Sciences Provides Corporate Updates in Advance of First Annual Pipeline Day
7/10/2018
Myrtle Potter, former President and COO of Genentech, appointed Vant Operating Chair
-
Enzyvant Announces Initiation of RVT-802 Rolling BLA Submission for the Treatment of Complete DiGeorge Anomaly
7/9/2018
Rolling BLA submission has been agreed to by FDA and is intended to expedite the Agency's review process
-
Dermavant to Present at JMP Securities Life Science Conference
6/19/2018
Dermavant announced that President and Chief Operating Officer Vince Ippolito will present a corporate overview at the JMP Securities Life Science Conference
-
Roivant to Host First Annual Pipeline Day
6/12/2018
Event to highlight recent developments and future directions for Roivant
-
Oxford BioMedica and Axovant Sciences enter into a $842.5 Million Exclusive Worldwide Licence Agreement for OXB-102 for the Treatment of Parkinson’s Disease
6/6/2018
~ Conference call for analysts to be held at 2:30pm BST / 9:30am ET (see details below)
-
Roivant Expands Senior Leadership with Key Hires
5/16/2018
Dr. Sam Azoulay as Chief Medical Officer and Adele Gulfo as Chief of Commercial Development
-
monARC Bionetworks Announces Strategic Integration with Roivant Drug Development Platform to Accelerate Delivery of New Medicines
5/3/2018
monARC Bionetworks, a healthcare technology company that has built an end-to-end clinical research platform to facilitate greater collaboration between patients, physicians, and researchers involved in clinical trials, today announced that it has initiated a strategic integration with the drug development platform of Roivant Sciences.
-
Sanofi announced that Elias Zerhouni, head of Global Research and Development, is retiring on June 30. The company has appointed John Reed to replace him as of July 1.
-
Dermavant Sciences, a company founded by biotech guru Vivek Ramaswamy, tapped former GlaxoSmithKline dermatology division executive David Rubenstein as its new chief scientific officer.
-
Dermavant Expands Pipeline and Strengthens Executive Team with Key Hires
4/3/2018
Dermavant Sciences announced that it has expanded its pipeline by in-licensing an investigational drug for the treatment of multi-focal hyperhidrosis.
-
Roivant Sciences and ArQule Enter into License Agreement for Derazantinib in China
2/7/2018
Roivant Sciences and ArQule today announced the initiation of a collaboration to pursue the development of derazantinib, a pan-FGFR (fibroblast growth factor receptor) inhibitor, in Greater China.
-
Arbutus Announces Closing of the Second Tranche of a $116M Strategic Investment From Roivant Sciences
1/16/2018
The Tranche 2 closing represents the second of two tranches of Preferred Shares issued to Roivant.
-
Incyte Names New Member to Its Board of Directors
10/31/2017
Incyte Corporation today announced the appointment of Jacqualyn Fouse, Ph.D., as a new member of the Board of Directors, effective November 14, 2017.
-
Vivek Ramaswamy's parent company, Roivant Sciences, inked a development deal with Astra.
-
Arbutus Announces Closing of $50 Million First Tranche of $116.4 Million Strategic Investment From Roivant Sciences
10/16/2017
Arbutus Biopharma and Roivant Sciences announced the closing of the issue and sale of 500,000 convertible series A preferred shares by Arbutus to Roivant for gross proceeds to Arbutus of US$50 million (Tranche 1).
-
Dermavant Sciences Appoints Vince Ippolito As President And Chief Operating Officer
9/29/2017